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Abstract 
Objectives: The objectives of the OMERACT Stiffness special interest group are to 
characterize stiffness as an outcome in rheumatic disease and to identify and validate a 
stiffness patient-reported outcome (PRO) in rheumatology.  
Methods: At OMERACT 2016, international groups presented and discussed results of 
several concurrent research projects on stiffness: a literature review of rheumatoid arthritis 
(RA) stiffness PRO measures; qualitative investigation into the RA and polymyalgia 
rheumatica patient perspective of stiffness; data-driven stiffness conceptual model 
development; development and testing of an RA stiffness PRO measure; and quantitative 
work testing stiffness items in RA and psoriatic arthritis patients.  
Results: The literature review identified 52 individual stiffness PRO measures assessing 
morning or early morning stiffness severity/intensity or duration. Items were heterogeneous, 
had little or inconsistent psychometric property evidence and did not appear to have been 
developed according to PRO development guidelines. A poor match between current stiffness 
PROs and the conceptual model capturing the RA patient experience of stiffness was 
identified, highlighting a major flaw in PRO selection according to the OMERACT Filter 2.0.  
Conclusion: Discussions within the Stiffness SIG highlighted the importance of further 
research on stiffness and defined a research agenda.  
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Statement of contribution to the literature: We report an original literature review of 
stiffness patient-reported outcome measures in rheumatoid arthritis, and synthesis of 
international qualitative work investigating the patient experience of stiffness in rheumatic 
diseases presented at the OMERACT 2016 Stiffness special interest group session. This work 
advances current understanding regarding stiffness conceptualization and assessment across 
rheumatic conditions and represents original work. 
 
Original contributions of this article 
 
 
Introduction 
Stiffness affects 70-75% of people with rheumatoid arthritis (RA) regardless of treatment 
status (1) and 44-80% of patients in low disease activity (2). Recent evidence shows that 
stiffness is important to patients with RA in flare (3) and remission (2) states, and it is an 
integral part of the RA experience (4, 5). Stiffness adversely affects health-related quality of 
life (6) and is associated with earlier initiation of disease-modifying therapy in RA (7).   
Furthermore, stiffness is a key symptom recognized by patients and clinicians in many other 
inflammatory rheumatic diseases including polymyalgia rheumatica (PMR) and psoriatic 
arthritis (PsA) among others (8-12). In RA, stiffness assessment is particularly relevant as it 
x An original literature review of stiffness patient-reported outcome measures in 
rheumatoid arthritis 
x A synthesis of results from international qualitative work investigating the 
rheumatoid arthritis patient experience of stiffness in rheumatoid arthritis 
x The first attempt to consolidate efforts regarding the understanding and 
assessment of stiffness in inflammatory rheumatic conditions   
x
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OLNHO\LQIOXHQFHVSDWLHQWV¶DELOLW\WRPHHWUHPLVVLRQFULWHULD(13). A recent systematic review (2) 
in RA low disease activity and remission identified and summarized the measurement 
properties of currently available stiffness patient-reported outcome (PRO) measures. The 
review identified only two articles, which made conflicting recommendations about the most 
appropriate concept for stiffness assessment (morning stiffness duration or severity), and 
concluded that there was insufficient scientific data supporting current stiffness measures (2). 
The aim of the OMERACT 2016 stiffness special interest group (SIG) is to consolidate work 
on stiffness across inflammatory rheumatic conditions in order to systematize future research 
on the topic, and work towards identifying and validating an outcome measure for stiffness in 
rheumatic diseases that is consistent with methodology outlined by the OMERACT Filter 2.0 
(14).  In preparation for the Stiffness SIG at OMERACT 2016 the following research projects 
were conducted: 1) a literature review of stiffness PRO measure in RA; 2) a synthesis of 
qualitative research conducted in RA; 3) qualitative research with patients with PMR; 4) 
development, refinement and testing of candidate items for an RA stiffness questionnaire (30); 
and 5) examination of stiffness items in RA and PsA.  
 
Stiffness literature review 
A literature review was conducted to identify and assess measurement properties of stiffness 
PROs in RA. The search was conducted in PubMed using a validated search filter (15) and 
was consistent with a prior systematic literature review in RA remission (2), including articles 
identified there. Article screening determined 25 articles suitable for full text review (Figure 1). 
From these, 52 individual stiffness PRO measures were identified. All but one assessed 
morning stiffness or early morning stiffness. Most assessed the concepts of duration (n=30) 
or severity/intensity (n=18), while others assessed improvement (n=1), importance (n=1), and 
two were unclear. There was great variation in PRO wording, response options, format and 
timeframe. For example, PRO item formats included visual analogue scale (VAS) (n=14), 
numeric rating scale (NRS) (5), Likert scale (n=7), minutes in free text (n=23), and two items 
were unclear. Items were also poorly defined with 22 items unclear regarding some or all item 
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components. Reports of face, content, criterion and construct validity, reliability and 
responsiveness were limited and inconsistent. Overall, severity items appeared to perform 
better than duration items in relation to construct validity, discrimination between disease 
states, responsiveness, and sensitivity to change but evidence was limited. No articles 
reported the face or content validity of stiffness items and no patient involvement in item 
development was reported. A summary of the literature review findings is outlined in Table 1. 
In conclusion, current RA stiffness assessment is heterogeneous, incompletely reported and 
does not appear to have been developed according to PRO development guidelines 
recommending incorporating the patient perspective (16).  
 
Qualitative investigation of stiffness in RA 
A synthesis of qualitative work capturing the RA patient experience of stiffness was performed 
by an experienced qualitative researcher. The published papers reviewed (4) (5) reported two 
independent conceptual models based on inductive thematic analysis (17, 18) of international 
focus groups and semi-structured interviews. The synthesis identified six common domains 
(Figure 2). Patients considered stiffness a normal part of RA that was widely variable (in timing, 
duration and location) and did not occur exclusively in the mornings. Stiffness was related to 
other RA symptoms, impacted on daily life, and was influenced by external or personal factors 
(e.g. medication, self-management). The key, common concepts, that stiffness is not purely a 
morning symptom and is best evaluated by its impact (19), contrast with current stiffness 
assessments, which focus on morning stiffness severity or duration. This indicates a poor 
match between the conceptual model and currently used PROs, a major flaw according to 
OMERACT Filter 2.0 recommendations for selecting PROs (20). 
 
Qualitative investigation of stiffness in PMR  
Qualitative research was conducted in PMR to investigate the patient experience of stiffness 
and its assessment (21) through eight focus groups.  The conceptual model of the PMR patient 
experience of stiffnHVVKDGIRXUPDMRUWKHPHVµV\PSWRPV¶µIXQFWLRQDOLPSDFW¶µLPSDFWRQGDLO\
7 
VFKHGXOH¶ DQG µDSSURDFKHV WR PHDVXUHPHQW¶ 6WLIIQHVV ZDV DQ LPSRUWDQW V\PSWRP IRU
SDWLHQWVGLVWLQFWIURPSDLQDQGIRUVRPHLWZDVµRYHUZKHOPLQJ¶DQGLPSRVHGUHVWULFWLRQVRQ
activities of daily life. For stiffness assessment, patients preferred an NRS or assessment of 
stiffness impact on daily life functioning rather than a VAS. Findings in PMR are consistent 
with qualitative work performed in RA.  Assessing functional impact may be a pragmatic 
approach to difficulties with current stiffness assessments.   
 
Development of new RA stiffness questionnaire 
A new PRO for stiffness in RA has been developed based on qualitative research findings (4), 
qualitative investigation into the patient perspective of stiffness assessment, and an iterative 
process of item development involving clinicians, researchers and patients. Cognitive 
interviews with RA patients refined draft items into a set of 45 preliminary stiffness items. 
These were administered via a postal survey with additional PROs (patient global assessment 
VAS (22); pain NRS (23); Bristol Rheumatoid Arthritis Fatigue Severity NRS (24, 25); flare 
question from the Preliminary Flare Questionnaire (26); Modified Health Assessment 
Questionnaire (MHAQ) (27); Patient-based Disease Activity Score (28, 29)) and demographic 
questions to a new sample of patients with RA (n=277, 32.9% male, mean (SD) age 63.9 
(12.4) years, range=23-97, median disease duration (IQR) 6 (3-15) years, range=1-45). 
Successive rounds of analytical refinement were performed using principal component 
analysis and &URQEDFK¶V DOSKD IRU LQWHUQDO FRQVLVWHQF\ WR LGHQWLI\ WKH VPDOOHVW QXPEHU RI
informative items. This resulted in the development of a new RA stiffness PRO measure 
5$67ZLWKLWHPVDQGWKUHHFRPSRQHQWVFDSWXULQJVWLIIQHVVµVHYHULW\¶ µSK\VLFDO LPSDFW¶
DQGµSV\FKRVRFLDOLPSDFW¶(30). The RAST PRO measure can now be tested in independent 
longitudinal studies to accumulate evidence on psychometric properties in RA and other 
rheumatic diseases. 
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Quantitative testing of stiffness items in RA and PsA 
Stiffness items (severity, duration and impact) were assessed in a cross-sectional study of 
patients with PsA and age and sex-matched RA controls in the Australian Rheumatology 
Association Database (31), a voluntary national registry for patients with inflammatory arthritis. 
Stiffness items and additional PROs (MHAQ (27), pain, patient global assessment) were 
completed electronically by 103/158 patients with PsA and 111/158 with RA. Ratings of 
stiffness severity, duration and impact were comparable in RA and PsA. There was a high 
degree of correlation between different dimensions of stiffness (r=0.71-0.89) and stiffness item 
formats (r=0.58-0.90). Stiffness was independently associated with physical function in the 
multiple regression model. Stiffness severity and impact were most strongly associated with 
physical function (adjusted R2=0.60).  
 
Discussion 
Stiffness is an important symptom for patients across rheumatic conditions. It has been 
included in the RA Flare core domain set since 2014 and its inclusion in the PMR core domain 
set and the research agenda for PsA was endorsed at OMERACT 2016. Qualitative research 
and literature reviews demonstrate that current stiffness PROs may not adequately reflect 
stiffness dimensions that matter most to patients (2, 4, 5, 8). Hence, current stiffness items do 
QRWPHHW WKH20(5$&7)LOWHU µH\HEDOO WHVW¶RIEHLQJDJRRGPDWFKZLWK WKHGRPDLQRI
interest (20). Discussions within the SIG suggested that while stiffness is a generalizable 
domain across several rheumatic conditions, notable differences exist in the patient 
experience. For example, patients within the SIG highlighted that the location of stiffness 
would differ between PMR and RA and this should be reflected in the wording of items. This 
is also relevant in AS or PsA with axial spondyloarthritis. Possible solutions could include 
further qualitative investigation with different patient groups to tailor assessments to specific 
populations, or design of a comprehensive databank of stiffness items that can be 
administered using an interactive approach like computer adaptive testing. Meanwhile, 
research to develop and validate a comprehensive RA stiffness PRO measure is currently 
9 
ongoing in the UK, US and Australia. This work has been grounded on qualitative research 
with patients and followed by item testing and refinement. Further testing and refinement in 
independent RA cohorts and additional rheumatic diseases is ongoing. 
 
Research agenda 
The OMERACT 2016 Stiffness SIG defined the following items on its research agenda: 1) 
investigation of contextual factors and adverse events which can be achieved through 
secondary data analysis of two qualitative datasets we collected in RA, PMR qualitative 
dataset as well as additional qualitative datasets (PsA); 2) qualitative investigation into the 
patient perspective of stiffness assessment in rheumatic diseases other than RA and PMR; 3) 
development and validation of stiffness assessment tools in RA. This may include further 
psychometric evaluations of the RAST and testing using item response theory; 4) investigation 
into stiffness pathophysiology across rheumatic conditions; and 5) review of stiffness 
assessment in osteoarthritis and non-rheumatic conditions to assess potential for integration 
with rheumatic disease stiffness. 
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Table 1: Individual stiffness PRO measures identified in literature review 
Author Instrument concept Stem wording Response options/anchors 
Rhind et al, 
1987 
1) Severity of MS 
2) Severity of MS 
3) Severity of MS 
 
4) Duration of MS 
1) EWU  
2) EWU 
3) EWU  
 
4) How long did it take for your stiffness to begin to 
ease after you got out of bed this morning? 
1) 10cm VAS; no-very severe 
2) 11-point NRS; no-very severe 
3) 5-point VS; no, mild, moderate, 
severe, very severe 
4) Mins 
Hazes et al, 
1993 
1) Severity of MS 
2) Severity of MS 
3) Duration of MS 
 
4) Duration of MS 
 
5) Duration of MS 
1) EWU  
2) EWU 
3) How long does you MS last until it begins to 
improve? 
4) How long does your MS last until maximum 
improvement occurs? 
5) How long does it take you to get going properly? 
1) 10cm VAS; no-very severe 
2) 11-point NRS; no-very severe 
3) Mins  
 
4) Mins 
 
5) Mins 
Hazes et al, 
1994 
1) Duration of MS 
2) Duration of MS  
3) Duration of MS 
4) Duration of MS 
5) Duration of MS 
6) Duration of MS 
1) Waking to first improvement 
2) Getting up to first improvement 
3) Waking to maximum improvement 
4) Getting up to maximum improvement 
5) Waking to complete disappearance 
6) Getting up to complete disappearance 
1) Mins  
2) Mins 
3) Mins 
4) Mins 
5) Mins 
6) Mins 
Ward, 1994 1) Duration of MS 1) EWU  1) Mins 
Buchbinder et 
al, 1995 
1) Duration of MS 1) Time from awakening; EWU 1) Mins, as time from awakening 
Borstlap et al, 
1995 
1) No mention of severity 
or duration 
1) EWU  1) 10cm VAS; anchors unclear 
Vliet Vlieland 
et al, 1997 
1) Severity of MS 
2) Duration of MS 
1) EWU  
2) How long does your morning stiffness last from 
waking until maximum improvement occurs? 
1) 10cm VAS; none-very severe 
2) Mins; cut-off at 240 
Houssien et al, 
1997 
1) Duration of EMS 1) EWU 1) Mins 
Wolfe, 1999 1) Severity of MS 
 
1) How severe has your stiffness been after you first 
woke up in the morning? 
1) 100mm VAS; none-extreme 
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Author Instrument concept Stem wording Response options/anchors 
2) Severity after 
immobility 
2) How severe has your stiffness been after sitting or 
lying down or while resting later in the day? 
2) 100mm VAS; none-extreme 
Fransen et al, 
2000 
1) Duration of MS 1) Were your joints stiff when you woke up today? If 
yes, how long did this extra stiffness last? 
1) 0mins, <30mins, 30 mins-1hr, 1-
2hrs, 2-4hrs, >4hrs <all day, all day 
Sarzi-Puttini et 
al, 2002 
1) Duration of MS 1) EWU  1) Mins on a VAS? Anchors unclear 
Leeb et al, 
2003 
1) Daily MS severity  
2) Starting stiffness after 
a time of rest 
3) Duration of MS 
1) EWU  
2) Starting stiffness after a time of rest, exact wording 
unclear  
3) EWU  
1) 100mm VAS; no-unbearable 
2) 100mm VAS; no-unbearable 
 
3) Mins 
Yazici et al, 
2004 
1) Duration of MS 1) EWU  1) 0mins, 1-15mins, 16-59mins, 
PLQV 
Westhoff et al, 
2008 
1) Severity of MS 
 
2) Duration of MS 
1) EWU 
 
2) EWU 
1) 11-point NRS; no-extremely 
severe 
2) Mins 
Khan et al, 
2009 
1) Duration of MS 1) From time of waking to time of max improvement 1) 0mins, 1-30mins, 31-60mins, 
>60mins 
El Miedany et 
al, 2010 
1) Duration of MS 1) Over the last week when you awakened in the 
morning, did you feel stiff? Please indicate the number 
of minutes, or hours until you are as limber as you will 
be for the day 
1) Mins 
Wiesinger et 
al, 2013 
1) No mention of severity 
or duration 
1) EWU  1) Anchors unclear 
Jastrzabek et 
al, 2013 
1) Duration of MS 1) EWU 1) Mins 
Lie et al, 2014 1) Severity of MS 
 
2) Duration of MS 
1) How would you describe the overall level of morning 
stiffness you have had from the time you wake up? 
2) How long does your morning stiffness last from the 
time you wake up? 
1) 10cm VAS; none-very severe 
 
2) 10cm VAS; 0=0hrs 10=>2hrs 
Bykerk et al, 
2014 
1) Severity of MS 
2) Duration of MS 
3) Stiffness severity 
1) EWU 
2) EWU  
3) EWU 
1) Response options unclear 
2) Response options unclear 
3) 11-point NRS; anchors unclear 
Hamad et al, 
2014 
1) Duration of MS 1) How long does your MS last until maximum 
improvement occurs? 
1) Mins 
14 
Author Instrument concept Stem wording Response options/anchors 
Bartlett et al, 
2015 
1) Stiffness 
2) Duration of MS 
1) Stiffness; EWU 
2) Were your joints stiff when you woke up today? If 
yes, how long did this extra stiffness last? 
1) 11-point NRS; anchors unclear 
2) 0mins, <30mins, 30 mins-1hr, 1-
2hrs, 2-4hrs, >4hrs <all day, all day 
Nies et al, 
2015* 
1) Duration or MS 
2) Duration or MS 
 
 
3) Duration or MS 
 
 
4) Severity of MS 
1) Do you experience stiffness when you get up in the 
morning? If so for how many minutes? 
2) Do you experience morning stiffness? If yes, for how 
long? 
3) Do you experience in stiffness in your joints in the 
morning. And if so, how long does this stiffness 
endures? 
4) EWU  
1) MLQVRUDQGRU 
2) MLQVRUDQGRU 
 
 
3) MLQVRUDQGRU 
 
 
4) 100mm VAS; mild=0-33, 
moderate=34-67, severe=68-100 
Ward et al, 
2015a 
1) Severity of MS 
2) MS transition 
 
3) MS transition 
importance 
1) EWU 
2) Since the start of the study, my stiffness in the 
PRUQLQJKDV«¶ 
3) MS transition importance, EWU 
1) 100mm VAS; none-very severe 
2) 3-point VS; improved, stayed the 
same, worsened 
3) 7-point VS; hardly important at all-
extremely important 
Ward et al, 
2015b 
1) Duration of MS 1) How long does your MS last until maximum 
improvement occurs? 
1) Mins 
PROMs=patient-reported outcome measures; MS=morning stiffness; EMS=early morning stiffness; VAS=visual analogue scale; NRS=numerical rating 
scale; VS=verbal scale; EWU=exact wording unclear; mins=minutes; *=different cohorts used different questions 
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Figure 1: Flow diagram of the article selection process 
 
 
Figure 2: Synthesis of patient-derived conceptual models of stiffness in RA 
 
